losartan has been researched along with atrasentan in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Boemke, W; Francis, RC; Höhne, C; Kaczmarczyk, G | 1 |
| Boemke, W; Francis, RC; Höhne, C; Kaisers, U; Klein, A; Pickerodt, P | 1 |
| Agharazii, M; Bélanger, S; Larivière, R; Lebel, M; Lemieux, P; Therrien, F | 1 |
| Certíková Chábová, V; Červenka, L; Husková, Z; Kramer, HJ; Kujal, P; Skaroupková, P; Tesař, V; Vaněčková, I; Vaňourková, Z; Vernerová, Z | 1 |
| Andress, DL; Bijlsma, MJ; de Zeeuw, D; Heerspink, HJ; Kröpelin, TF; Parving, HH; Persson, F | 1 |
| El-Din, MM; El-Mas, MM; Elmallah, AI; Khedr, MM; Nasser, SA; Sabra, R | 1 |
| Alpers, CE; Hudkins, KL; Steegh, F; Wietecha, TA | 1 |
7 other study(ies) available for losartan and atrasentan
| Article | Year |
|---|---|
Effect of angiotensin II and endothelin-1 receptor blockade on the haemodynamic and hormonal changes after acute blood loss and after retransfusion in conscious dogs.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Blood Transfusion; Cardiac Output; Dogs; Endothelin-1; Epinephrine; Female; Glomerular Filtration Rate; Hemodynamics; Hemorrhage; Losartan; Norepinephrine; Pyrrolidines; Receptor, Endothelin A; Stroke Volume; Urine; Vascular Resistance; Vasopressins | 2004 |
ETA-receptor blockade impairs vasoconstriction after hemorrhage in xenon-anesthetized dogs treated with an AT1-receptor antagonist.
Topics: Anesthesia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Blood Pressure; Dogs; Endothelin A Receptor Antagonists; Endothelin-1; Female; Hemodynamics; Hemorrhage; Losartan; Pyrrolidines; Vascular Resistance; Vasoconstriction; Vasopressins; Xenon | 2008 |
Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Endothelin-1; Hydralazine; Hypertension, Malignant; Losartan; Male; Necrosis; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renal Insufficiency | 2009 |
Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasentan; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Hypertension, Renal; Indoles; Kidney; Losartan; Male; Nephrectomy; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Receptor, Endothelin A; Renal Insufficiency, Chronic; Renin-Angiotensin System; Survival Analysis; Treatment Outcome | 2012 |
Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.
Topics: Aged; Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrasentan; Bone Density Conservation Agents; Diabetic Nephropathies; Endothelin Receptor Antagonists; Ergocalciferols; Female; Fumarates; Humans; Losartan; Male; Middle Aged; Office Visits; Pyrrolidines; Randomized Controlled Trials as Topic; Research Design; Statistics as Topic; Urine Specimen Collection | 2015 |
Facilitation by the renin-angiotensin system of cyclosporine-evoked hypertension in rats: Role of arterial baroreflexes and vasoreactivity.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Angiotensin II; Animals; Aorta; Atrasentan; Baroreflex; Blood Pressure; Captopril; Cyclosporine; Hypertension; Indomethacin; Losartan; Male; Naphthalenes; Nitric Oxide Synthase Type III; Nitroprusside; Oligopeptides; Phenylephrine; Piperidines; Propionates; Pyrrolidines; Rats; Renin-Angiotensin System; Vasoconstriction; Vasodilation | 2016 |
Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Losartan; Mice; Phosphorylation; Podocytes; Proteinuria; Renin-Angiotensin System; Ribosomal Protein S6 Kinases; TOR Serine-Threonine Kinases | 2020 |